PolyMedix, Inc. (PYMX.OB) Commences Phase 2 Trials for Systemic Antibiotic
PolyMedix Inc. is an emerging biotechnology company focused on therapeutic drugs to treat serious acute cardiovascular disorders and infectious diseases. The company today announced that it has initiated a phase II clinical trial in Canada for its novel defensin-mimetic antibiotic PMX-30063. Designed to mimic the activity of the body’s natural defense against bacterial infections, PMX-30063 is the first and only systemic antibiotic of its kind. The phase II trial will enroll up to 200 patients at multiple sites in Canada with a desired end-point to determine the safety and efficacy of PMX-30063 for the treatment of acute bacterial skin and…